Skip to main content
Akero Therapeutics, Inc. logo

Akero Therapeutics, Inc. — Investor Relations & Filings

Ticker · AKRO ISIN · US00973Y1082 LEI · 549300SI3KG74LBE2955 US Professional, scientific and technical activities
Open in API
Filings indexed 719 across all filing types
Latest filing 2019-06-17 Regulatory Filings
Country US United States of America
Listing US AKRO

About Akero Therapeutics, Inc.

https://akerotx.com/

Akero Therapeutics, Inc. is a clinical-stage company focused on developing and commercializing transformational treatments for patients with serious metabolic diseases characterized by high unmet medical need. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). EFX is being evaluated in multiple clinical trials as a potential foundational therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease. The program aims to provide a differentiated treatment that addresses the complex pathophysiology of MASH by restoring metabolic balance.

Recent filings

Filing Released Lang Actions
8-A12B
Regulatory Filings Classification · 95% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934. It includes details about the registration of common stock on The Nasdaq Stock Market. The document is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. It is not an announcement of a report but the actual registration statement form. Therefore, it fits best under Regulatory Filings (RNS). The document length is 3807 characters, which is relatively short but contains the full registration form text, not just an announcement.
2019-06-17 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a correspondence letter addressed to the SEC regarding a Registration Statement on Form S-1. It discusses the distribution of a Preliminary Prospectus and requests acceleration of the effectiveness of the Registration Statement. There is no financial data, report content, or detailed analysis present. The document is short (1909 characters) and serves as a regulatory communication related to a capital raising process, specifically a registration statement filing. This fits the category of a Regulatory Filing (RNS) rather than a full report or announcement of a report publication.
2019-06-17 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-1. It is a formal communication related to the registration process of securities, specifically requesting the SEC to declare the registration statement effective earlier than originally planned. The document does not contain financial statements, audit information, or detailed report content. It is a regulatory communication related to capital raising but is not itself a capital/financing update report or a registration statement filing. Given its nature as a formal regulatory communication, it best fits under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory documents that do not fit other specific categories. The document length is short and it is not an announcement of a report publication, so RPA is not appropriate. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2019-06-17 English
S-1/A
Capital/Financing Update Classification · 95% confidence The document is an Amendment No. 1 to Form S-1 Registration Statement filed with the SEC by Akero Therapeutics, Inc. It is a registration statement under the Securities Act of 1933, used for initial public offerings (IPOs) or other securities offerings. The text includes details about the offering, number of shares, pricing, underwriting, and other offering-related information. It is not an annual report, earnings release, or any other financial report type. It is a capital markets filing related to the registration and offering of securities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not RPA or RNS. Confidence is high due to clear identification of the form and content.
2019-06-10 English
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a detailed letter from Akero Therapeutics, Inc. to the U.S. Securities and Exchange Commission regarding their Registration Statement on Form S-1 for an initial public offering (IPO). It discusses confidential treatment requests, valuation methodologies for common stock prior to the IPO, and the estimated preliminary price range for the offering. The document references the Registration Statement on Form S-1 multiple times and provides detailed explanations about stock valuation and pricing, which are typical components of IPO registration filings. This is not a full annual or quarterly report, nor is it an earnings release or a call transcript. It is also not a proxy statement, voting results, or a management change announcement. The document is a regulatory filing related to the IPO registration process and responses to SEC comments, which fits best under the category of Regulatory Filings (RNS). The document is lengthy (15,000 characters) and contains substantive content, but it is not the report itself (Form S-1) but rather correspondence and supplemental information related to it, which is typical for RNS filings.
2019-05-24 English
S-1
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for initial public offerings (IPOs). It includes a preliminary prospectus with detailed information about the offering, risk factors, use of proceeds, capitalization, dilution, selected financial data, management discussion and analysis, business description, management, executive compensation, principal stockholders, and legal matters. The document is not an annual report, earnings release, or any other type of periodic financial report. Instead, it is a capital markets filing related to the company's initial public offering and registration of securities. According to the filing definitions, updates on company fundraising or capital structure changes fall under Capital/Financing Update (CAP). Since this is a registration statement for an IPO, it is best classified as a Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full prospectus, not just an announcement of a report, so it is not RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2019-05-24 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.